Form 4: Aptevo Director Granted 7,200 Restricted Stock Units

Aptevo Therapeutics Inc. director Grady Grant III was granted 7,200 Restricted Stock Units, vesting on the first anniversary of the grant date.

Summary

• Director Grady Grant III received a grant of 7,200 Restricted Stock Units (RSUs) on August 6, 2025.
• Each RSU converts into one share of Aptevo Therapeutics Inc. common stock.
• The RSUs vest in full on the first anniversary of the grant date, which is August 6, 2026.
• Following this transaction, Grady Grant III beneficially owns 7,200 Restricted Stock Units directly.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive sign of continued commitment and aligns the director's interests with long-term shareholder value, indicating stability in governance.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with long-term shareholder value, as the value of the compensation is tied to the company's stock performance.

Future Outlook

The Restricted Stock Units granted are scheduled to vest in full on August 6, 2026, which will convert them into common stock.

Industry Context

Equity grants, such as Restricted Stock Units, are a common form of compensation for directors and executives across various industries, including biotechnology, to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• The grant of Restricted Stock Units to a director is a standard practice for executive and board member compensation within the biotechnology and broader corporate sectors.
• The specific number of units (7,200) would typically be evaluated in the context of the director's overall compensation package, the company's size, and peer group compensation benchmarks, which are not detailed in this filing.

Related Party Transactions

• The grant of Restricted Stock Units to a director constitutes a related party transaction, which is a standard compensation practice.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the company's stock performance, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• Vesting of the 7,200 Restricted Stock Units on August 6, 2026.

Key Dates

Recommendation

This Form 4 reports a routine equity compensation grant to a director, which is a standard practice to align management interests with shareholders. It does not contain information significant enough to alter an investment thesis based solely on this filing, thus a 'hold' recommendation is appropriate.

Keywords

Aptevo Therapeutics, APVO, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, Form 4